Skip to main content

Table 5 Predictors of treatment failure in HIV-positive adults on MDR-TB treatment at Sizwe Tropical Disease Hospital, Johannesburg

From: Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa

  aUnivariable Analysis bMultivariable Analysis
Factor IRR (95 % CI) p-value IRR (95 % CI) p-value
ART regimen     
 After 1.00   1.00  
 Prior 1.01 (0.47–2.15) 0.988 0.80 (0.35–1.84) 0.606
Age groups     
 18–45 1.00    
 46–76 0.79 (0.27–2.28) 0.662   
BMI 0.97 (0.87–1.07) 0.547 1.01 (0.94–1.09) 0.766
Haemoglobin (g/dl)     
 Severe Anaemia (<7.0) 2.69 (0.78–9.30) 0.117 4.72 (1.47–15.08) 0.009*
 Moderate Anaemia (7.0–9.99) 1.09 (0.46–2.57) 0.839 0.97 (0.40–2.34) 0.944
 Mild Anaemia (10–10.99) 0.43 (0.10–1.87) 0.260 0.25 (0.03–1.82) 0.172
 Normal (≥11) 1.00   1.00  
Infiltrative changes     
 No 1.00    
 Yes 1.01 (0.14–7.47) 0.990   
Cavitary changes     
 No 1.00   1.00  
 Yes 1.81 (0.85–3.87) 0.125 2.14 (0.96–4.78) 0.064
Fibrotic changes     
 No 1.00    
 Yes 1.36 (0.41–4.50) 0.620   
Comorbidity     
 No 1.00   1.00  
 Yes 1.79 (0.72–4.41) 0.207 2.39 (1.05–5.43) 0.039*
Adverse events     
 No 1.00   1.00  
 Yes 0.54 (0.24–1.23) 0.142 0.48 (0.21–1.09) 0.080
Regimen type at baseline     
 Standardised 1.00   1.00  
 Modified individualised 2.48 (1.18–5.20) 0.016* 2.15 (0.98–4.71) 0.056
  1. IRR Incidence rate ratio
  2. aUnadjusted models
  3. bAdjusted for Co-trimoxazole prophylaxis, BMI and categories of MDR-TB
  4. *Significant p <0.05